A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a
 day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine
 (once a day), Bolus Insulin Lispro (three times a day), and Metformin Therapy, in subjects
 with Type 2 Diabetes Mellitus who have inadequate glycemic control.
Inclusion Criteria:

 -  Have been taking a basal insulin Glargine, at dose of ≥ 20 units/day, for at least 3
 months prior to study start.

 -  Have been taking basal insulin Glargine at dose of ≥ 20 units/day, in combination with
 1 of the following oral antidiabetic medication (OAM) regimens, for at least 3 months
 prior to study start:

 -  Metformin or immediate-release metformin or extended-release metformin alone at a
 maximum tolerated and stable dose with no less than 500 mg/day for at least 6
 weeks prior to study start; or

 -  Metformin or immediate-release metformin or extended-release metformin at a
 maximum tolerated and stable dose with no less than 500 mg/day for at least 6
 weeks prior to study start and sulfonylurea at a stable dose for 6 weeks prior to
 study start.

 -  Have an HbA1C > 7.0% and ≤ 10.0%.

 -  Have a body mass index (BMI) between ≥ 25 and ≤ 45 kg/m2.

 Exclusion Criteria:

 -  Are currently taking OAM that is not described above and not allowed with concurrent
 use of insulin per local product label.

 -  Have taken more than 1 week within 1 month prior to the study start any
 glucose-lowering medications not included above either alone or in combination
 formulations, or have used a drug for weight loss (for example, prescription drugs
 such as orlistat, sibutramine, phenylpropanolamine, rimonabant or similar
 over-the-counter medications).

 -  Have taken any insulin other than Glargine within the 3 months prior to study start
 for more than 1 week.

 -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
 (excluding topical, intraocular, and inhaled preparations) within 4 weeks prior to the
 study start.

 -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
 trial involving an off-label use of an investigational drug or device (other than the
 study drug/device used in this study), or concurrently enrolled in any other type of
 medical research judged not to be scientifically or medically compatible with this
 study.

 -  Have previously completed or been withdrawn from this study after enrollment.